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Summary 
Evaluation of human histocompatibility leukocyte antigen (HLA) class II genes in 54 cases of 
tuberculoid leprosy (TL) and 44 controls has shown a positive association with HLA-DRB1 al- 
leles that contain Arg  13 or Arg7~  71. Among TL patients, 87% carry specific alleles of DRB1 
Arg  13 or ArgT~  71 as compared to 43% among controls (p =  5  ￿  10 -6) conferring a relative 
risk  of 8.8.  Thus,  susceptibility to  TL involves three  critical amino  acid positions of the  [3 
chain,  the side  chains  of which, when modeled on the DR1  crystal structure, line a pocket 
(pocket 4) accommodating the side  chain of a bound peptide. This study suggests  that disease 
susceptibility may be  determined by the  independent contribution of polymorphic residues 
participating in the formation of a functional arrangement (i.e., pocket) within the binding cleft 
of an HLA molecule. 
L 
eprosy is a chronic infectious disease  caused by a rela- 
tively nontoxic microorganism, Mycobacterium  leprae. In 
the natural history ofM. leprae infection, >95% of individ- 
uals  resist  disease  by establishing protective immunity and 
only the minority develops leprosy (1).  Nevertheless, lep- 
rosy is a major world health problem affecting an estimated 
10.6  million  patients  in  the  world  of which  two  thirds 
(62%)  are found in Southeast Asia  and 34% in Africa  (2). 
Once leprosy becomes established, there is a wide spectrum 
of clinical  manifestations.  Tuberculoid leprosy (TL)  1 and 
lepromatous  leprosy  (LL)  are  two  opposite  poles  in  the 
spectrum,  representing  stable  disease  forms  with  distinct 
immunopathological and clinical findings. Borderline lep- 
rosy is an intermediate, unstable  form of the disease  with 
clinical  and  pathological manifestations  between  the  two 
poles (2). 
TL is  the localized, hyperactive form of leprosy. As  in 
healthy, exposed individuals, the lepromin skin test is posi- 
tive and there is a vigorous in vitro proliferation of PBL to 
1  Abbreviations used in this paper: LL, lepromatous leprosy; rr, relative risk; 
TL, tuberculoid  leprosy. 
L. Zerva  and B. Cizman contributed  equally to this paper. 
mycobacterial antigens. However, in the skin lesions, very 
few if any acid-fast bacilli are present (3). At the other end 
of the spectrum, LL is the anergic, widespread form of lep- 
rosy. Macrophages loaded with acid-fast bacilli accumulate 
in the lesions, but the lepromin test is negative and PBL do 
not proliferate in vitro to M.  leprae antigens  (3).  It appears 
that  different immunopathogenic  mechanisms  operate  in 
different disease  forms.  Since  there  is  no  association be- 
tween disease forms and different M.  leprae strains or expo- 
sure levels to M.  leprae, the reaction of the host may deter- 
mine the form of the disease that develops. Previous family 
and  population  studies  have  linked  these  host  factors  to 
HLA class II molecules. 
In Asian-Indian families with leprosy, TL was associated 
with DR2  (4).  This association has  also  been detected in 
sporadic  TL patients  from ethnically diverse populations, 
e.g., India, Japan.  Thailand, and Korea (5-11), whereas an 
association  with  DR.3  has  been  reported in  two  distinct 
populations from Venezuela and Surinam  (12,  13).  In re- 
gard to LL, although early reports suggested that the Dl<2 
association involves only TL  (5,  8,  12,  14),  other subse- 
quent reports do not confirm this finding (7, 9,  15-17). In 
all these studies,  serological HLA typing was  employed as 
the typing method, therefore, HLA differences at the too- 
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evaluated. 
HLA  molecules  are  receptor  cell-surface  glycoproteins 
that bind peptides and present them to the T  cells  (18,  19). 
This interaction causes stimulation of the T  cell and activa- 
tion of an immune response.  There are class I and II HLA 
molecules  with  different  domain  organization  but  similar 
structure  (20, 21). Polymorphic residues in both class I and 
I! molecules  are  clustered  within  the  peptide-binding  re- 
gion and are responsible for the different peptide specifici- 
ties  observed  for  different  histocompatibility  molecules. 
Both  class  I  and  II molecules  have  allele-specific  binding 
motifs  (22,  23).  Peptides  bound  to  class  I  are  of defined 
length  (8-10  residues);  their  motifs  are  characterized by a 
strong preference for a few side chains at some positions in 
the peptide and wide tolerance for many side chains at the 
other positions  (24).  Peptides  bound to  class  II molecules 
are longer with  no  apparent  restriction  on peptide  length 
(25,  26).  The  main chain  atoms  of the  peptides  form hy- 
drogen bonds with HLA residues conserved in most class II 
alleles,  and the side chains are accommodated by polymor- 
phic pockets in the binding site.  These pockets  appear  to 
determine  the  peptide  specificity of different  class  II pro- 
teins  (27).  Polymorphic  residues  in  the  binding  cleft  of 
HLA class  II molecules,  therefore,  control  the  binding  of 
foreign  peptides,  and  indirectly,  the  immune  response  to 
these  peptides.  The  objective  of this  study  was  to  use  a 
DNA-based typing procedure to identify polymorphic res- 
idues within  the binding cleft that may be associated with 
the disease, TL. 
Materials  and Methods 
Populations Tested and Statistical Analysis.  54 unrelated patients 
with sporadic TL were randomly selected from major hospitals in 
Delhi. These patients  were from the north Indian states of Pun- 
jab,  Haryana,  Uttar,  Pradesh,  Bihar,  and Delhi.  None  of them 
had a history of familial leprosy.  The patients  were classified ac- 
cording to the tLidley and Jopling criteria  (28) by clinical exami- 
nation and a review of  their clinical histories. Skin-slit smear bacte- 
riology and histopathological  examination  of  skin biopsy specimens 
were performed in all patients.  Preliminary results on the typing 
of some of the patients  have been previously published  (29). 44 
unrelated healthy individuals  constituted the control group. None 
of them had a family history of leprosy.  They were all matched 
with  patients  for socioeconomic status  and  were  living in  the 
same area as the patients. 
The chi square test with Yates' correction was used to evaluate 
the differences  of the allelic frequencies  between various  groups. 
To correct for the multiple  comparisons carried out, the apparent 
significance level was multiplied by the number of statistical tests 
(30). Fisher's exact test was used to determine the statistical signif- 
icance of the differences  between the subtypes  of DIL6-positive 
TL patients  and controls because  of the relatively low number of 
subjects involved in those cases. For haplotypes showing a statisti- 
cally  significant  difference  in  frequency  between  patients  and 
controls, relative risk was calculated  as: rr =  [Pd (1-Pc)]/[1-Pd) 
Pc], where Pd and Pc are  the frequencies  of individuals  positive 
for the allele(s) among patients  and controls,  respectively. 
DNA Extraction.  A  standard  phenol-chloroform  extraction 
method (31) was used for the isolation  of high molecular weight 
genomic DNA from whole blood samples and from a reference 
panel ofB lymphoblastoid cell lines (32) that constituted the pos- 
itive and negative controls for the amplification  and hybridization 
reactions. 
PCR Amplification of Genomic DNA.  Locus  and  allele-spe- 
cific amplifications  of genomic DNA with the PCP,, were per- 
formed for D1LBI-, DtLB3-, DR.B4-, DILB5-, and DQBl-asso- 
ciated alleles. The primers used in the PCtL and the amplification 
conditions  have  been  described  earlier  (31).  Cycling was  per- 
formed with a thermal cycler (model 9600;  Perkin-Elmer Cetus 
Corp.,  Norwalk,  CT).  Amplified samples were  electrophoresed 
in a 1% agarose gel containing ethidium bromide and were visu- 
alized under UV light. 
Dot Blot and Hybridization.  Amplified  DNA was  blotted  on 
Hybond N+  nylon transfer  membranes  (Amersham Corp.,  Ar- 
lington Heights,  IL). The membranes were hybridized with the 
probes  in  a  hybridization incubator  (P,  obbins  Scientific  Corp., 
Sunnyvale,  CA).  A  panel  of sequence-specific  oligonucleotide 
probes (SSOP),  described  earlier  (31), was used with some modi- 
fications.  The oligonucleotide probes were labeled  with  digoxi- 
genin-11-dUTP (Boehringer Mannheim Corp., Indianapolis,  IN) 
using terminal  deoxynucleotidyl transferase  (Boehringer Mann- 
helm)  according to  the  manufacturer's  instructions.  The  labels 
were  detected  by  sheep  anti-digoxigenin  antibody  fragments 
(Fab) conjugated to alkaline phosphatase  (Boehringer-Mannheim) 
diluted  at  150  mU/ml.  Nitro  blue  tetrazolium  and  5-bromo- 
4-chloro-3-indolyl phosphate (all from Sigma Chemical Co., St. 
Louis, MO) were used as the chromogenic substrates. 
Results  and Discussion 
54 unrelated sporadic cases of TL and 44 healthy controls 
from  northern  India  were  typed  for  HLA  class  II  genes 
(DRB1, B3, B4, B5, and DQB1) by amplification of DNA 
with the  PCIL and hybridization with SSOP.  Frequencies 
of the HLA-DRB1  alleles  in the  control population were 
similar  to  those  reported  for  other  Asian-Indian  popula- 
tions  (5,  33,  34).  The  number  of individuals  positive  for 
each of the different D1LBI* alleles  in the two populations 
of TL patients  and  controls is  shown in Table  1.  Notice- 
ably,  none  of the  alleles  as  defined  by DNA-based  HLA 
typing  shows  a  statistically  significant  difference  between 
control and TL patients. 
However, upon careful evaluation,  there are certain dif- 
ferences between the two populations that are very instruc- 
tive.  The  comparable  frequency of alleles  1501  and  1502 
within  TL and  control  groups  (32  vs 37%  in  TL patients 
and  14  vs  18%  in  control  subjects)  suggests  that  none  of 
these  two alleles  has an advantage over the  other in terms 
of disease  susceptibility.  Therefore,  the  single  amino  acid 
difference [V(1501) --) G(1502)] at codon 86 does not play 
a major role in disease  susceptibility  and  allows these  two 
alleles  to  be  considered  as  a  single  entity  (DRBl*15). 
However, as shown in Table 2, the number of TL patients 
positive for DRB1*15 (1501  +  1502) is significantly higher 
as compared to the number of control individuals  positive 
for the same alleles  (TL [37 of 54] 69%; control [14 of 44] 
32%;  uncorrected p  =  0.0007  and corrected for nine tests 
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Alleles  Patients  Controls  rr  Corrected p  Patients  Controls 
(n =  54)  (n --- 44) 
Alleles  n  ~  n  %  Corrected p 
n  =  54  %  n  =  44  % 
DRBI*15  37  69  14  32  4.7  0.0063* 
DRBI*0101  3*  6  4  9  NS* 
DRBI*0102  0  --  1  -- 
DRBI*1501  17  32  6  14  NS 
DRB1*1502  20  37  8  18  NS 
DRBI*1602  1  --  1  -- 
DR_BI*0301  6  11  12  27  NS 
DPd31*0401  1  --  2  -- 
DRBI*0403  2  --  3  7  NS 
DRBI*0406  1  --  0  -- 
DRBI*0409  0  --  1  -- 
DRBl*1101  4  7  3  7  NS 
DRBl*1103  0  --  1  -- 
DRBl*1104  1  --  1  -- 
DRB1*1106  0  --  1  -- 
DRB1*1201  0  --  2  -- 
DRB1*1202  2  --  1  -- 
DRBl*1301  4  7  8  18  NS 
DRB1*1302  1  --  0  -- 
DRBI*1401  1  --  0  -- 
DRB1*1402  0  --  1  -- 
DRBl*1403  0  --  1  -- 
DRBl*1404  12  22  4  9  NS 
DRBI*0701  9  17  15  34  NS 
DR_BI*0803  0  --  2  -- 
DR_B1*0901  2  --  1  -- 
DPd31*1001  9  17  3  7  NS 
*Number of individuals  positive for a particular  DRB1 allele. 
*Statistical analysis was performed in 10 out of 26 DRB1  alleles. The 
remaining 16 were not tested  for statistical differences  because  two or 
fewer instances were observed in both control and TL patients, 
p  =  0.0063,  rr  =  4.7).  This  suggests  the  presence  of 
epitope(s)  on the DRB1*15  sequence  that  is important  for 
TL susceptibility.  Additionally,  among DR6-positive  indi- 
viduals  (DR6  includes  DRB1*13  and  DRB1*14  alleles), 
only  two  alleles  occur  with  reasonable  frequencies  in  our 
population,  namely  DRB1*1301  and  DRBl*1404  (Table 
2).  It was  observed that the frequencies of these two alleles 
in  the  TL  patients  and  controls  were  characterized  by  an 
inverse  relationship.  Among  TL  patients  (Table  2)  there 
was  an increased number  of cases positive for DRB1*1404 
(12  of 16,  75%)  as  compared  to  controls  (4  of 12,  33%; 
p  =  0.034)  and  a  decreased  number  of TL  cases  positive 
for DRB1*1301  (4  of 16,  25%)  as  compared  to  controls 
(8 of  12,  67%;  p  =  0.034).  DRBl*1404  was  also  in- 
creased  among  DR2-negative  (DR2  includes  DRBl*15 
DR6positives  n=  16  %  n=  12  % 
DRBl*1301  4  25  8  67  0.17  0.033 ;~ 
DRBl*1404  12  75  4  33  6  0.033 
DR2negatives  n=  15  %  n=  27  % 
DRBl*1404  6  40  1  4  7.1  0.034~ 
*Statistical analysis was performed in 10 out of 26 DRB1 alleles. The 
remaining 16 were not tested  for statistical differences because  two or 
fewer instances were observed in both control and TL patients.  The p 
value correction factor  is therefore 9  (DRB1*1501  and DRBl*1502 
were combined into one allele). 
*Fisher's exact test was used to determine statistical significance  in this 
group. 
~Statistical analysis was performed in 7 out of 18 alleles present in the 
DR2-negative individuals.  The remaining 11 were not tested for statis- 
tical differences because  two or fewer instances were observed in both 
control and TL patients.  The p value correction factor is therefore 7. 
and DRBI*16  alleles)  TL patients  (6  of 15,  40%)  as com- 
pared to DR2-negative  controls  (1  of 27, 4%); uncorrected 
p  =  0.0048,  and  corrected for seven tests p  =  0.034  with 
rr=  7.1  (Table  2).  Since  alleles  DRB1*1301  and 
DRBl*1404  are splits of the serologic specificity DR6,  this 
inverse relationship  of the two subtypes  may very well ex- 
plain  why,  in  previous  serological studies,  the  importance 
of the DR6  specificity went undetected. 
The  identification  of  the  DRB1*15  alleles  that  were 
positively  associated  with  TL,  the  significantly  increased 
numbers  of TL  patients  positive  for  DRBl*1404  among 
DRB1*15  negative  cases,  and  the  inverse  relationship  of 
DRBI*1301  and DRB1*1404  alleles among DR6-positive 
control  and  TL  individuals  focused  our  attention  on  the 
amino  acid residues  that  were  different between  the nega- 
tively and  positively associated  allelic forms.  We  reasoned 
that  the  most  important  amino  acid  positions  for  disease 
susceptibility would be those that differed in the negatively 
as  compared  to  the  positively  associated  alleles.  These 
amino  acid residues  were  found  to  be located  at positions 
[313, [537, [570, and [571 (Fig.  1). The two positively associated 
alleles  DRBl*15  and  DRB1*1404  were  characterized  by 
arginines at positions [313 and [37~  respectively. Addition- 
ally, it was noticed that the DRBl*1301  allele is character- 
ized by S 13, D 7~  and E vl which represent a  negative charge, 
whereas DRB1*1404  is characterized by G 13, R 7~  and R 71, 
which  represent  a  positive  charge.  Disease  association  was 
therefore  reexamined  using  the  presence  of  arginine  at 
these three positions  and the absence of negatively charged 
amino acids in any of the same positions as criteria, regard- 
less  of  allelic  typing.  Those  alleles  include  DRBl*1501 
(R13,  Q70, A71), DRBl*1502  (R  13, q70, A71),  DRBl*1401 
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Figure 1.  Residues  that differ among DR. alleles that are positively and negatively associated with TL. Amino acid residues are indicated that are differ- 
ent between DRB1*1301 and DRBl*1404 or between DRB1*1301 and DRB1*15 allele. Residues at positions 13, 37, 70, and 71 were different in both 
comparisons. DRBl*1301  (S13N37D7~ 71) "--q'  DPd31*1404 (GI3F37R7~  or --) DRB1*15 (R13S37Q7~ 
(S 13, R 7~  R71),  DR_B1*1404  (G 13, R 7~  R71),  DRBI*0901 
(F 13, R 7~  R.71), and DRBI*1001  (F 13, R.  7~  R;1). As shown 
in table 3, the phenotype Arg  13 positive or Arg  70/71 positive 
was  overrepresented  among patients  as  compared  to  con- 
trols (TL patients  [47 of 54]  87%;  controls  [19 of 44]  43%; 
p  =  5  ￿  10 -6,  IT 8.8).  Characteristically,  most of the pa- 
tients were  DRB1-Arg ~3 positive  (37  of 54,  69%).  Among 
those  patients  that  lacked  DRB1  alleles  with  Arg  13,  there 
was a significant increase in DRBt  alleles that were positive 
for Arg  7~  (TL patients  [10 of 16]  63%;  controls  [5  of 29] 
17%; p  =  0.003). 
When  the  criterion  of association  was  expanded  to  in- 
clude  alleles  with  any positive  charges  at positions  1313 or 
~70/71,  alleles  DRBI*0401  (H 13,  QT0, K71),  DRBI*0403 
(H13  QV0,  R7I),  DRBI*0406  (H 13,  Q70,  R71),  and 
DRBI*0409  (H 13,  QT0,  K71) were  also  counted  among 
those  that  could  confer  susceptibility.  In  addition  to  the 
DRBI*04  alleles,  no  others  satisfied  this  criterion  in  our 
population.  Statistical analysis showed that by including the 
DRBl*04 alleles within the group of alleles that confer sus- 
ceptibility,  the p  value  of "positive charge at positions  613 
or [37~  (TL patients  [49 of 54]  92%;  controls  [23  of 44] 
52%; p  =  25  ￿  10 -6)  did not show a better association as 
compared  to the p  value  of "Arg  I3 or Arg  7~  (p  =  5  ￿ 
10 -6) whereas rr was at a comparable level (8.9 vs 8.8)  (Ta- 
ble  3).  The  frequency  of all DRBI*04  alleles  combined 
in the Asian-Indian  population  is between  7  and  10%  (33, 
34),  which  is  comparable  with  that  of DRBl*14  alleles. 
If these  DRBI*04  alleles  were  positively  associated  with 
the disease there should have been an increased frequency, 
though  not  neccessarily  statistically  significant,  of TL  pa- 
tients positive for DR4 as compared to controls.  However, 
such  an  increased  frequency  was  not  observed  (Table  1). 
Table 3.  Association of DRB1 Shared Epitopes with TL 
Epitopes  Patients  Controls  rr  p 
p13 or 1~  70/71 
RI3 
Positive charge at 
~13 or ~70/71 
R 13 negatives 
p~70/71 
n=  54  %  n=  44  % 
47  87  19  43  8.8  5 X  10 -6 
37  69  14  32  4.7  0.0003 
49  90  23  52  8.9  25  5< 10 .6 
n=  16  %  n=29  % 
10  63  5  17  7.1  0.003 
Therefore,  the  positive  charge  at  positions  [313 or  ~70/71 
did not improve the association with the disease, and it is un- 
likely that the alleles DRBI*0401, DRBI*0403, DRBI*0406, 
and DRBI*0409  are among those that confer susceptibility. 
The  absence  of statistically  significant  differences  in  the 
numbers  of individual  DRB1  alleles  between  TL patients 
and controls in contrast to the highly statistically significant 
difference for Arg  13, Arg  7~  in the same population is very 
likely due to the relatively small size of the population sam- 
ple  analyzed  and  to  the  typing method  employed  (DNA- 
based typing),  which  substantially increases  the  number  of 
detected  alleles.  However,  irrespective  of the  absence  of 
statistically  significant  alMic  differences,  the  DNA-based 
typing  has  provided  amino  acid  sequence  information, 
hence,  eliminating the  need  to establish allelic  associations 
before  a  valid  association  can  be  established  at the  amino 
acid  level.  Therefore,  identification  of particular  amino 
acid(s)/epitopes  present  in  more  than  one  allele  and  pre- 
disposing  to  disease  susceptibility  may become  apparent 
by  studying  populations,  whose  size  can  be  smaller,  as 
compared  to  the  large  size of a  population  that would  be 
required  if allehc  associations  were  to be  established.  Rare 
alleles such as DRB1*1401  and DRBI*0901  that are repre- 
sented  in  1-3%  of this  population  would  only  signifi- 
cantly  increase  in  a  population  of over  1,000  individuals. 
DRBI*1001,  which is a more frequent allele (4-6%) in this 
population  (33, 34), already shows the tendency of an asso- 
ciation  (p  =  0.18)  yet does not reach significant levels. No 
definitive statement, therefore, can be made concerning the 
association  of these  three  alleles  with  TL.  However,  the 
presence of Arg  7~  in their DR[3 chains suggests that these 
alleles may play a role in disease susceptibility. 
The amino acid substitution at position 37 was not found 
to be significantly different between patients and controls. 
To examine whether other HLA genes within the MHC 
that are in linkage disequilibrium  with  HLA-DRB1  alleles 
influence  the  association  of TL,  the  distribution  of the  al- 
lelic forms ofDRB3, DRB4, DRB5, and DQB1 genes was 
evaluated. No significant differences were found in the fre- 
quencies  of these alleles between  TL patients  and  controls 
(data  not  shown).  Furthermore,  no  linkage  disequilibrium 
was identified  between Arg at position  13  or 70/71  of the 
DRB1  gene and other DRB or DQB genes. 
It  is  noteworthy  that  from  the  crystal  structure  of  a 
HLA-DR  molecule the side chains of positions  13, 70, and 
71  are in  close proximity  (19,  20),  and  that  charge  differ- 
ences  in  the  local  environment  may affect the  binding  of 
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A).  Reminiscent  of this  observation is  the  finding that  in 
HLA-DR.1, the side chains of residues 13, 70, and 71 line a 
pocket, pocket 4  (Fig.  2  B)  that accommodates a Gln side 
chain from the hemagglutinin peptide (27).  The exact crys- 
tallographic structure of other HLA-DR. alleles with an Arg 
at positions 13 or 70 and 71 is not known. It is very likely, 
however, that the side chains of these amino acids will also 
contribute to the formation of this pocket. 
Our finding suggests that the presence of Arg at positions 
13  or 70/71  in pocket 4  of the DRB1  alleles  confers sus- 
ceptibility to TL. We propose that the presence of a posi- 
tive charge generated by Arg at positions 13 primarily or 70 
and 71  secondarily may influence  a critical site within the 
binding groove of the DR. chain that affects peptide bind- 
ing and/or T  cell interactions in the immune response asso- 
ciated with TL. In support of this hypothesis are a number 
Figure  2.  Presentation  of amino acids forming pocket 4 of the DP,.1 
crystal structure. (,4) Crystal structure is shown as spherical model where 
ct chain is shown in white and 13 chain in yellow. The pictures are gener- 
ated using GRASP (35). The three residues 1313 Phe (blue),  1370 Gin (green), 
and [371 Arg (red)  are  shown on the structure. (B) Pocket formation is 
shown as dotted surface. The walls of the pocket are formed by residues 
13  70  7I  74  78  13  Phe (blue),  13  Gin (green),  13  Arg (red),  13  Ala  (yellow),  13  Tyr (yel- 
9  2  low), and o~  Gin (white).  These residues are within 12 A  distances. 
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of in vitro studies performed independently by other inves- 
tigators  (36-38)  wherein  positions  13,  70,  and  71  were 
shown to be direcdy involved in antigen-specific T  cell re- 
sponses. These studies have examined the amino acid resi- 
dues at various positions of the DR.~3 chain that are impor- 
tant for antigen-specific T  cell  recognition. By employing 
L  cell transs  expressing a  single DR  allele and site- 
directed  mutagenesis  it  has  been  determined  that  among 
amino acid residues 9,  11,  13, 28, 30, and 37 that are local- 
ized to the floor of the binding groove, substitutions at po- 
sition  13  more  frequently  eliminated  T  cell  recognition 
than substitutions at any of the other five positions (36-38). 
Additionally,  substitutions  in  the  r  at  positions  70, 
71, and 74 could drastically affect T  cell responses (36-38). 
Furthermore, studies on the association of MHC class II 
molecules with chronic autoimmune disorders have shown 
that amino acids at positions  67,  70,  71,  and 74  of HLA- 
DRB 1 are associated with susceptibility to rheumatoid ar- 
thritis.  In rheumatoid arthritis,  the DRB1  alleles  associated 
with  the  disease  involve amino  acid substitutions  at posi- 
tions 70, 71, and 74 that change the local charge of the re- 
gion affected by these amino acids to a more positive one 
(39,  40).  Recently,  characterization  of peptides  bound  to 
the  DRBI*04  alleles  which  are  positively  (DRBI*0404) 
and  negatively  (DRBI*0402)  associated with  rheumatoid 
arthritis  revealed  that  both  alleles  have  identical  require- 
ments at the anchor residue pl  and at p6 but a substantially 
different  requirement  at  position  p4  (41).  DRBI"0404 
binds peptides with a negative charge at p4 whereas the re- 
verse is true for DRBI*0402  which binds peptides with a 
positive charge at the same position.  Since these two HLA 
alleles are different in positions 67, 70, and 71 and positions 
70  and  71  participate in  the  formation of pocket 4,  these 
findings emphasize the importance of the structural charac- 
teristics of these HLA alleles at this region and strongly sug- 
gest that pocket 4 of these two HLA molecules determines 
the kind ofpeptides that will be accommodated. 
Another illustration  of the  importance  of this  region  is 
the  reported association of chronic beryllium disease with 
certain DPB1  alleles.  A  change at position 69 of the DPB1 
gene from a lysine to a glutamic acid has been reported to 
be  associated  with  chronic  beryllium  disease,  a  lung  dis- 
order related to beryllium exposure,  and  characterized by 
the  accumulation in  the  lung of beryllium-specific CD4 § 
MHC class II-restricted T  lymphocytes (42).  It is notewor- 
thy that position 69 of the DP[3 chain corresponds to posi- 
tion  71  of the  Dtk[3  chain  and  that  the  amino  acids  in- 
volved  cause  a  major  charge  shift  from  positive  (R.) to 
negative (E). 
The importance of a similar region in  class I  molecules 
has been previously indicated by other studies (43)  that in- 
volve  virus-specific,  Kb-restricted  cytotoxic  effector  cells 
responding to K b mutants.  The bm  1 mutant with altered 
amino acids at positions  152,  155,  and  156 is the only one 
that affects the virus-specific cytotoxic effector cells so that 
characteristically,  all  clones  lose  their  reactivity  (43).  It is 
interesting  that  none  of the  other bm mutants  affects the 
cytotoxic cells  so uniformly.  These positions in the  class I molecule  correspond  to  positions  66,  69,  and  70  of the 
DR[3  chain.  Thus,  both class  I  and  II molecules appear to 
influence  T  cell recognition by changes in amino acids lo- 
cated  in  equivalent  portions  of the  HLA  molecule  (class 
I-orS6/class II-[37~ 
These independently reported observations using in vitro 
functional analysis oft  cell clones and HLA disease associ- 
ation studies are, therefore, consistent with our conclusions 
that specific positions on the HLA [3 chains define a critical 
site that appears to play a more pronounced  role in T  cell 
recognition and activation. This effect may be the result of 
more  than  one  amino  acid  substitution.  A  particular  site 
within the groove may be influenced by several amino acid 
positions.  Indeed,  the formation of pockets as illustrated  in 
the  crystal  of  DRl-influenza  peptide  suggests  that  the 
binding  of a  foreign peptide  is influenced  by a  number  of 
side chains lining a particular pocket on the HLA molecule. 
Characteristically,  pocket 4  is formed by the side chains  of 
amino acids e0 [313, [3v0, [37l,  [374, and [378. Substitutions  on 
any  of these  positions  that  would  affect  the  local  charge 
such  as Arg at position  13  or Arg  at positions  70  and  71 
may both  have  the  same  effect as  they  will  probably  ac- 
commodate the binding of a negatively charged residue  of 
the foreign peptide.  This may indeed be the  case as it has 
been  reported  that  HLA-DRw17  (DRBI*0301),  which 
has arginine  instead  of alanine  at position  [374,  prefers as- 
partate or glutamate at the position that corresponds to he- 
magglutinin  glutamine  311  (44,  45).  The presence  of Arg 
at 74 may also explain the reported association of TL with 
DR3 in two ethnic  groups (12,  13). When these polymor- 
phic  positions  that  form  the  pocket  involve  substitutions 
that result in potent charge modifications,  the binding of a 
peptide  or of a TCR  may be affected, provided the intro- 
duced modifications result in a net gaining or losing charge. 
However the  apparent  lack of association  with  DRBI*04 
alleles, which have a histidine  at [313, suggests that the mere 
presence of a positive charge in this region may not be ade- 
quate and that arginine is instrumental in terms of selecting 
the appropriate peptide for binding, 
In our study involving TL patients,  the association with 
HLA-DR  alleles  including  DR2  was  confirmed.  Further- 
more,  it  appears  that  the  associations  of DR[3  Arg  13  or 
Arg  7~  with TL may be specific for this form of the  dis- 
ease, A  recent study examining TL and control individuals 
from the same geographical area as our population  (46)  by 
HLA  oligotyping,  reported  the  increased  frequency  of 
DRBl*15  alleles but did not detect the inverse relationship 
of DRBI*1301  and DRB1*1404  within the DR6-positive 
individuals.  This may be related to the rather small number 
of cases (28 TL patients) who were examined. 
In TL, it is likely that peptide(s)  originating from M.  lep- 
rae binds  preferentially  to  HLA allelic  forms characterized 
by Arg at positions  13 or 70-71  and stimulates particular T 
cell clones that result in a detrimental immune response of 
TL. Identification  of peptide motifs that bind the  different 
allelic  forms  associated  with  the  disease  would  contribute 
significantly to the  search for M.  teprae antigenic  determi- 
nants that initiate this response, and possibly for self-protein 
and peptides that become the targets.  Our findings suggest 
that the disease-associated alleles will be characterized by a 
binding motif that includes a negatively charged amino acid 
at  position  4  (numbering  is  based  on  the  hemagglutinin 
peptide that binds DR1  [27]). 
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